Research programme: anticancer monoclonal antibodies - Precision Biologics

Drug Profile

Research programme: anticancer monoclonal antibodies - Precision Biologics

Alternative Names: 16C3 antibody; 31.1 antibody; 31.1 monoclonal antibody; h16C3 monoclonal antibody; NEO-201; NEO-301; Sq-1; Sq-2

Latest Information Update: 25 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Neogenix Oncology
  • Developer National Cancer Institute (USA); Precision Biologics
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Neoplasm antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Solid tumours
  • No development reported Colorectal cancer; Pancreatic cancer

Most Recent Events

  • 21 Apr 2018 Pharmacodynamics data from preclinical studies in Cancer presented at the 109th Annual Meeting of American Association for Cancer Research (AACR-2018)
  • 26 Mar 2018 Precision Biologics and the National Cancer Institute plan a phase I trial for Solid tumours (Second-line therapy or greater, Recurrent, Inoperable/Unresectable, Metastatic disease) in USA (NCT03476681)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Colorectal-cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top